相关实验视频

Updated: Jul 6, 2026

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening

Published on: January 17, 2014

症状性Dientamoeba fragilis感染的治疗结果:一个前性的临床和分子研究

Asaf Biber^1,2,3, Dafna Yahav^1,3, Eli Schwartz^4,5

¹Infectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel.

|February 23, 2026

概括

帕罗摩辛是对Dientamoeba fragilis (DF) 感染最有效的治疗方法,其治愈率很高. 临床恢复与寄生虫根除有很强的相关性,支持DF.

科学领域:

胃肠病学胃肠病学
传染性疾病传染性疾病
临床微生物学临床微生物学

背景情况:

慢性胃肠道问题患者中经常检测到Dientamoeba fragilis (DF),但其临床意义和最佳治疗仍在争论中.
无法解释的慢性胃肠道症状需要考虑DF感染.

研究的目的:

评估对各种抗寄生虫治疗Dientamoeba fragilis (DF) 感染的临床和分子反应.
评估DF感染患者的症状缓解和寄生虫根除之间的关联.

主要方法:

前性,单中心观察性研究 (2019年1月至2023年6月),包括105名症状患者,便PCR为DF呈阳性.
患者接受了帕罗摩辛 (PAR),尼特罗伊米达单疗法 (NM) 或丁多加阿尔本达 (T+A).
临床和分子结局在治疗后一个月通过问卷和重复PCR测试来评估.

主要成果:

与T+A (35.0%/29.2%) 和NM (4.2%/10.0%) 相比,帕罗摩辛 (PAR) 的临床 (82.8%) 和分子 (88.5%) 治愈率显著更高.
在临床治愈和DF根除之间发现了强烈的相关性 (p < 0.00001),支持DF的致病作用.
转诊前的症状持续时间中位数为9个月,突出显示未经治疗的DF感染的慢性性质.

结论:

帕罗摩辛是对Dientamoeba fragilis (DF) 感染最有效的治疗方法,临床恢复和微生物治疗之间有着强烈的联系.
建议进行分子测试,以准确诊断DF.
需要进一步的随机对照试验来建立最佳的DF管理策略.

关键词:

艾尔本达醇 (Albendazole) 是一种一种抗原动物治疗治疗.临床疗法可以治愈.D. fragilis的病原性是因为它的病原性.胃肠道症状胃肠道症状甲尼达的使用方法分子诊断是一种分子诊断.这是一个PCRPCR.帕罗莫米辛是一种可怕的药物.提尼达 (Tinidazole) 是一种可以使用的药物.

更多相关视频

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Identification of Mycobacterium Species by DNA Microarray Chip Method

Identification of Mycobacterium Species by DNA Microarray Chip Method

Published on: June 24, 2025

相关概念视频

Cryptococcal Meningitis

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...

Amebiasis

Amebiasis

Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...

Anthelminthic Agents

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...